论文部分内容阅读
近年来人类白细胞抗原(HLA)半相合治疗恶性血液病有了很大的进展,其与HLA全相合相比具有供者来源方便的优点,但HLA半相合存在着移植物抗宿主病重、免疫重建迟、致死性感染发生率高、移植相关病死率和疾病复发率高等诸多问题。本研究从预处理方案、移植物抗宿主病的预防、选择性的去除T细胞策略、骨髓间充质干细胞和自然杀伤细胞的输注等方面进行综述。
In recent years, human leukocyte antigen (HLA) haploidentical treatment of hematological malignancies have made great progress, which has advantages of convenient donor source compared with HLA full conformation, but HLA haploidentical graft-versus-host disease is serious, immune Delayed reconstruction, the incidence of fatal infections, graft-related mortality and disease recurrence rate and many other issues. In this study, we reviewed the strategies of pretreatment, prevention of graft-versus-host disease, selective removal of T cells, infusion of bone marrow mesenchymal stem cells and natural killer cells.